Pharmocotherapy Principles and Practice- Benign Prostatic Hyperplasia
Contact Hours: 1.5
ACPE No: 014-999-07-064-H04
Activity Type:
Release Date:
Expiration Date:
Learning Objectives
Upon completion of this activity the participant should be able to:
Upon completion of the chapter, the reader will be able to:
1. Explain the pathophysiologic mechanisms underlying the symptoms and signs of benign prostatic hyperplasia.
2. Recognize the symptoms and signs of benign prostatic hyperplasia in individual patients.
3. List the desired treatment outcomes for a patient with benign prostatic hyperplasia.
4. Identify factors that guide selection of a particular -adrenergic antagonist for an individual patient.
5. Compare and contrast -adrenergic antagonists versus 5-reductase inhibitors in terms of mechanism of action, treatment outcomes, adverse effects, and interactions when used for management of benign prostatic hyperplasia.
6. Describe the indications for combination drug treatment of benign prostatic hyperplasia.
7. Describe the indications for surgical intervention of benign prostatic hyperplasia.
8. Formulate a monitoring plan for a patient on a given drug treatment regimen based on patient-specific information.
9. Formulate appropriate counseling information for patients receiving drug treatment for benign prostatic hyperplasia.
Faculty:
Computer Requirements for Online Courses
PC
- Windows 2000 SE or greater
- Flash Player Plugin 9.0 or later
- Internet Explorer 6.0 or later OR Firefox 2.0 or later
- Sound Card & Speakers
- 800 x 600 Minimum Monitor Resolution (1024 x 768 Recommended)
- Adobe Acrobat Reader for viewing PDF's
MAC
- Mac OS 10.2.8
- Flash Player Plugin 9.0 or greater
- Safari 2.0 or above OR Firefox 2.0 or later
- Sound Card & Speakers
- 800 x 600 Minimum Monitor Resolution (1024 x 768 Recommended)
- Adobe Acrobat Reader for viewing PDF's'
The University of Georgia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.